Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Annexon (NASDAQ:ANNX) from an underperform rating to a market perform rating in a research report released on Thursday, MarketBeat.com reports.

Several other analysts also recently commented on ANNX. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Monday, July 13th. Wall Street Zen cut shares of Annexon from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Annexon in a research note on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. Finally, The Goldman Sachs Group began coverage on shares of Annexon in a research report on Tuesday, May 12th. They set a “neutral” rating and a $7.00 price target for the company. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $15.33.

Annexon Trading Up 0.6%

Annexon stock opened at $5.29 on Thursday. The business’s fifty day simple moving average is $5.35 and its two-hundred day simple moving average is $5.51. Annexon has a 12 month low of $2.03 and a 12 month high of $7.18. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -4.56 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last released its earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). On average, equities research analysts predict that Annexon will post -1 EPS for the current year.

Insider Buying and Selling

In other Annexon news, Director Muneer A. Satter bought 613,497 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was acquired at an average price of $5.41 per share, with a total value of $3,319,018.77. Following the transaction, the director owned 10,342,134 shares in the company, valued at $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 10.31% of the company’s stock.

Institutional Trading of Annexon

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Annexon by 65.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after purchasing an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Annexon in the fourth quarter worth approximately $50,000. CIBC Bancorp USA Inc. purchased a new stake in Annexon in the third quarter worth approximately $31,000. Mercer Global Advisors Inc. ADV purchased a new stake in Annexon in the fourth quarter worth approximately $52,000. Finally, Abel Hall LLC bought a new stake in Annexon in the 1st quarter worth approximately $61,000.

More Annexon News

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $14 price target, substantially above Annexon’s recent trading level. This indicates the firm continues to see significant potential upside despite lowering its earnings projections. HC Wainwright analyst estimates
• Neutral Sentiment: Citizens JMP upgraded Annexon to Market Perform, suggesting a more constructive stance but not an outright bullish recommendation. Citizens JMP upgrades Annexon
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including estimates of $(0.99) for 2026, $(0.74) for 2027, $(0.39) for 2028, $0.03 for 2029 and $0.45 for 2030. The cuts imply slower expected earnings improvement and could weigh on investor sentiment, even though the firm retained its Buy rating and $14 target. HC Wainwright lowers Annexon earnings estimates
• Negative Sentiment: Wall Street Zen lowered its rating on Annexon, adding another negative signal from the analyst community. Wall Street Zen lowers Annexon rating
• Negative Sentiment: Annexon shares previously gapped down after weak earnings. The company reported a quarterly loss of $0.28 per share, worse than the $0.24 consensus estimate, reinforcing concerns about ongoing cash needs and the timing of profitability. Annexon shares gap down following weak earnings

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.